CervoMed Inc. Logo

CervoMed Inc.

Developing CNS therapeutics for neurodegenerative diseases like dementia with Lewy bodies.

CRVO | US

Overview

Corporate Details

ISIN(s):
US2537484048 (+1 more)
LEI:
Country:
United States of America
Address:
20 PARK PLAZA, 2116 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related, neurodegenerative diseases. The company advances central nervous system (CNS) therapeutics by targeting synaptic dysfunction, the reversible aspect of the neurodegenerative process, in the early stages of disease. Its lead investigational product is neflamapimod, an orally administered, small molecule brain penetrant that inhibits the p38 alpha protein kinase. CervoMed is advancing neflamapimod through clinical trials, including a Phase 2 study for patients with dementia with Lewy bodies (DLB).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 13:08
Regulatory News Service
8-K - CervoMed Inc. (0001053691) (Filer)
English 80.6 KB

Automate Your Workflow. Get a real-time feed of all CervoMed Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CervoMed Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CervoMed Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Personalis, Inc. Logo
Cancer genomics & liquid biopsy for early recurrence detection & guiding precision therapies.
United States of America
PSNL
Perspective Therapeutics, Inc. Logo
Developing targeted alpha radiotherapies using lead-212 to image and treat solid tumors.
United States of America
CATX
PharmAbcine Inc. Logo
Develops antibody therapies for cancer, eye diseases, and vascular-related disorders.
South Korea
208340
Pharma Foods International Co., Ltd. Logo
Researches and sells functional ingredients and direct-to-consumer health & beauty products.
Japan
2929
Pharma Mar S.A. Logo
Develops and commercializes marine-derived oncology treatments for rare cancers.
Spain
PHM
Pharmanutra Logo
Researches and markets nutritional supplements & medical devices for all ages.
Italy
PHN
PHARMARESEARCH BIO Co., Ltd. Logo
A global biopharma firm creating regenerative medicine, pharmaceuticals, devices, and cosmetics.
South Korea
217950
PharmaResearch Co., Ltd. Logo
Develops regenerative medicine, devices & cosmetics using marine biotechnology.
South Korea
214450
PharmaSGP Holding SE Logo
Develops and markets leading natural OTC drugs for chronic conditions in the European market.
Germany
PSG
Pharmena S.A. Logo
Develops dietary supplements using its patented 1-MNA molecule to support healthy aging.
Poland
PHR

Talk to a Data Expert

Have a question? We'll get back to you promptly.